248 related articles for article (PubMed ID: 31421224)
1. MicroRNA-6077 enhances the sensitivity of patients-derived lung adenocarcinoma cells to anlotinib by repressing the activation of glucose transporter 1 pathway.
Ma DB; Qin MM; Shi L; Ding XM
Cell Signal; 2019 Dec; 64():109391. PubMed ID: 31421224
[TBL] [Abstract][Full Text] [Related]
2. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells.
Liang L; Hui K; Hu C; Wen Y; Yang S; Zhu P; Wang L; Xia Y; Qiao Y; Sun W; Fei J; Chen T; Zhao F; Yang B; Jiang X
J Exp Clin Cancer Res; 2019 Feb; 38(1):71. PubMed ID: 30755242
[TBL] [Abstract][Full Text] [Related]
3. Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling.
Qin T; Liu Z; Wang J; Xia J; Liu S; Jia Y; Liu H; Li K
Cancer Biol Med; 2020 Aug; 17(3):753-767. PubMed ID: 32944404
[No Abstract] [Full Text] [Related]
4. β-Sitosterol attenuates anlotinib resistance in non-small cell lung cancer cells by inhibiting miR-181a-3p/SHQ1 signaling.
Wang LH; Sun YH; Liu H; Yang X; Wen Z; Tian XF
Chem Biol Drug Des; 2024 Mar; 103(3):e14493. PubMed ID: 38439529
[TBL] [Abstract][Full Text] [Related]
5. Exosomal miR-136-5p Derived from Anlotinib-Resistant NSCLC Cells Confers Anlotinib Resistance in Non-Small Cell Lung Cancer Through Targeting PPP2R2A.
Gu G; Hu C; Hui K; Zhang H; Chen T; Zhang X; Jiang X
Int J Nanomedicine; 2021; 16():6329-6343. PubMed ID: 34556984
[TBL] [Abstract][Full Text] [Related]
6. NEAT 1 knockdown enhances the sensitivity of human non-small-cell lung cancer cells to anlotinib.
Gu G; Hu C; Hui K; Chen T; Zhang H; Jiang X
Aging (Albany NY); 2021 May; 13(10):13941-13953. PubMed ID: 33982669
[TBL] [Abstract][Full Text] [Related]
7. Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial.
Cheng Y; Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Zhu J
Cancer Med; 2020 Apr; 9(8):2621-2630. PubMed ID: 32064794
[TBL] [Abstract][Full Text] [Related]
8. Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the AKT pathway and promoting the apoptosis of CAFs in lung adenocarcinoma.
Tang H; You T; Ge H; Gao J; Wang Y; Bai C; Sun Z; Han Q; Zhao RC
Int Immunopharmacol; 2024 May; 133():112053. PubMed ID: 38615380
[TBL] [Abstract][Full Text] [Related]
9. [A Case Report of Advanced Lung Adenocarcinoma Harboring KRAS Mutation
Treated with Anlotinib].
Su Y; Meng Z; Xu X; Wang X; Zuo R; Hou Y; Li K; Chen P
Zhongguo Fei Ai Za Zhi; 2018 May; 21(5):428-430. PubMed ID: 29764596
[TBL] [Abstract][Full Text] [Related]
10. Silencing TRIM29 Sensitizes Non-small Cell Lung Cancer Cells to Anlotinib by Promoting Apoptosis
Wu M; Jin MM; Cao XH; Zhao L; Li YH
Curr Cancer Drug Targets; 2024; 24(4):445-454. PubMed ID: 37644752
[TBL] [Abstract][Full Text] [Related]
11. Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy.
Lu J; Zhong H; Chu T; Zhang X; Li R; Sun J; Zhong R; Yang Y; Alam MS; Lou Y; Xu J; Zhang Y; Wu J; Li X; Zhao X; Li K; Lu L; Han B
Eur Respir J; 2019 Mar; 53(3):. PubMed ID: 30578392
[TBL] [Abstract][Full Text] [Related]
12. Anlotinib enhances the antitumor activity of radiofrequency ablation on lung squamous cell carcinoma.
Zhou W; Gao Y; Tong Y; Wu Q; Zhou Y; Li Y
Pharmacol Res; 2021 Feb; 164():105392. PubMed ID: 33348023
[TBL] [Abstract][Full Text] [Related]
13. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
Zhou M; Chen X; Zhang H; Xia L; Tong X; Zou L; Hao R; Pan J; Zhao X; Chen D; Song Y; Qi Y; Tang L; Liu Z; Gao R; Shi Y; Yang Z
Cancer Commun (Lond); 2019 Jun; 39(1):36. PubMed ID: 31221221
[TBL] [Abstract][Full Text] [Related]
14. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; Cheng Y; He J; Shi Y; Zhao Y; Yu H; Zhao Y; Chen W; Luo Y; Wu L; Wang X; Pirker R; Nan K; Jin F; Dong J; Li B; Sun Y
JAMA Oncol; 2018 Nov; 4(11):1569-1575. PubMed ID: 30098152
[TBL] [Abstract][Full Text] [Related]
15. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
Si X; Zhang L; Wang H; Zhang X; Wang M; Han B; Li K; Wang Q; Shi J; Wang Z; Cheng Y; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Chen Y; Zhou J; Wang D
Lung Cancer; 2018 Aug; 122():32-37. PubMed ID: 30032842
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of anlotinib in 16 patients with advanced non-small cell lung cancer].
Si XY; Wang HP; Zhang XT; Wang MZ; Zhang L
Zhonghua Nei Ke Za Zhi; 2018 Nov; 57(11):830-834. PubMed ID: 30392239
[No Abstract] [Full Text] [Related]
17. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
18. [Intervention of Vascular Dysplasia Caused by Different Mechanisms - Anlotinib for Right Lung Squamous Cell Carcinoma Combined with Thromboangiitis Obliterans: A Case Report and Literature Review].
Hao H; Zhang M; Zhang G; Zhu H; Bao W
Zhongguo Fei Ai Za Zhi; 2020 Jan; 23(1):60-64. PubMed ID: 31948540
[TBL] [Abstract][Full Text] [Related]
19. miR-596 suppresses the expression of Survivin and enhances the sensitivity of osteosarcoma cells to the molecular targeting agent anlotinib.
Wang L; En H; Yang L; Zhang Y; Sun B; Gao J
Onco Targets Ther; 2019; 12():6825-6838. PubMed ID: 31686840
[TBL] [Abstract][Full Text] [Related]
20. Anlotinib exerts anti-cancer efficiency on lung cancer stem cells in vitro and in vivo through reducing NF-κB activity.
Li Z; Tian J; Du L; Gao Y; Wang Y; You F; Wang L
J Cell Mol Med; 2021 Jun; 25(12):5547-5559. PubMed ID: 33955683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
